Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02991898 · ClinicalTrials.gov registry record · Phase 2
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02991898: Clinical Trial Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT02991898 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02991898, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a single center pilot study of a non-myeloablative umbilical cord blood transplant for the treatment of a hematological malignancy with a single infusion of T regulatory (Treg) given shortly after UCB transplantation.
Primary Outcome
Count of patients who survived 2 years post intervention
Interventions
- BIOLOGICAL Infusion of Treg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-02-16 |
| Est. Completion | 2019-06-20 |
| Phase | Phase 2 |
Why NCT02991898 stopped before completion
NCT02991898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Infusion of Treg is the first listed.
NCT02991898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02991898 about?
NCT02991898 is a clinical study titled "Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies". This is a single center pilot study of a non-myeloablative umbilical cord blood transplant for the treatment of a hematological malignancy with a single infusion of T regulatory (Treg) given shortly after UCB transplantation.
What is the current status of trial NCT02991898?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-02-16. Estimated completion is 2019-06-20.
What interventions are being tested in trial NCT02991898?
The interventions under investigation include: Infusion of Treg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02991898?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02991898's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI